Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.18% | -7.99% | 3.98% | -54.26% | -58.79% |
| Depreciation & Amortization | -- | -- | -291.11% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.18% | -7.99% | -20.36% | -63.39% | -64.27% |
| Operating Income | -41.18% | 7.99% | 20.36% | 63.39% | 64.27% |
| Income Before Tax | -45.88% | 35.05% | 53.55% | 68.19% | 63.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.88% | 35.05% | 53.55% | 68.19% | 63.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 100.00% | -350.00% | -84.62% | -66.67% |
| Net Income | -46.21% | 35.21% | 53.34% | 68.05% | 63.87% |
| EBIT | -41.18% | 7.99% | 20.36% | 63.39% | 64.27% |
| EBITDA | -- | -- | 20.15% | 65.19% | 61.46% |
| EPS Basic | -222.22% | 85.88% | 59.21% | 68.06% | 96.50% |
| Normalized Basic EPS | -200.00% | 81.13% | 25.84% | 67.86% | 96.25% |
| EPS Diluted | -222.22% | 85.88% | 59.21% | 68.06% | 96.50% |
| Normalized Diluted EPS | -200.00% | 81.13% | 25.84% | 67.86% | 96.25% |
| Average Basic Shares Outstanding | -52.46% | 373.19% | 14.46% | 0.00% | 900.00% |
| Average Diluted Shares Outstanding | -52.46% | 373.19% | 14.46% | 0.00% | 900.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |